Niaspan and Advicor
are registered trademarks of Kos Life Sciences LLC.
Dyslipidemia includes sales of TriCor/Trilipix, Niaspan, Simcor and Advicor
The Company currently markets Niaspan, Advicor
, Azmacort, Cardizem LA, Teveten and Teveten HCT.
Since being founded in 1988 by our current Chairman Emeritus Michael Jaharis and Chairman Daniel Bell, Kos has pioneered the HDL therapy area in the United States and firmly established Niaspan and Advicor
as successful and highly differentiated therapies," said Adrian Adams, president and chief executive officer, Kos Pharmaceuticals.
KOSP's products include Niaspan for the treatment of mixed lipid disorders; Advicor
for the treatment of primary hypercholeterolimia and mixed dyslipidemia in patients previously treated with either component or who require additional lipid modification; and Azmacort product, an inhaled corticosteroid that alleviates inflammation in the lungs and is used as a treatment for asthma.
The Company currently markets Niaspan and Advicor
for the treatment of cholesterol disorders, Azmacort(R) for the treatment of asthma, Cardizem(R)LA for the treatment of hypertension and angina, and Teveten(R) and TevetenHCT for the treatment of hypertension.